NAB: Thorburn doing a good job
NAB's interim result wasn't great, but the focus right now is a raft of other announcements designed to exit the UK and fix the company's balance sheet.
Macquarie Group: Annual result 2015
Macquarie has posted its best quality result since the GFC but, as Nathan Bell explains, its current valuation leaves no room for error.
NAB: Interim result 2015
NAB's interim result wasn't great, but the focus right now is a raft of other announcements designed to exit the UK and fix the company's balance sheet.
TPG ups bid for iiNet
TPG has beaten M2's counterbid for iiNet - just - but there's likely more action to come in this Telecoms shakeout.
Commonwealth Bank: Q3 Result 2015
CBA has been criticised for not passing on the full rate cut, but its third quarter result explains why.
ANZ: Interim result 2015
ANZ's result provided more evidence that returns on equity might be peaking as bad debts bottom out.
Westpac: Interim result 2015
Westpac's underlying result was perhaps a bit better than it looked, but it's the underwritten dividend reinvestment plan that we're most disappointed by.
Lloyds: 2015 Q1 result
Lloyds's first quarter result was messy as usual, but all the important numbers were pointing in the right direction.
Is SMS Management a value trap?
Hot on the heels of last week's exposé of value traps, James Carlisle asks if this IT services provider may be a case in point.
Austbrokers: sins of commission
Changes in the insurance industry are filtering through to Austbrokers' bottom line. Will the trouble continue?
iCar Asia's road to riches
It'll take a few more years, but this auto classifieds business is well on the road to profitability.
M2 enters battle for iiNet
A bidding war has opened up for iiNet, with M2 Group trumping TPG's all-cash bid with a share-based offer.
ResMed's 'first-class problems'
ResMed's third-quarter results missed expectations, but it was, in part, a victim of its own success.
ResMed's 'first-class problems'
ResMed's third-quarter results missed expectations, but it was, in part, a victim of its own success.
GBST upgraded to Buy (again)
GBST is offering another bite after a broker downgraded its recommendation on the stock.
GBST upgraded back to Buy
GBST is offering another bite after a broker downgraded its recommendation on the stock.
Are Sirtex's best days behind it?
Sirtex shareholders have been on a rollercoaster ride. But are its latest clinical trial results really as bad as they look?
IRESS targets UK market
IRESS is looking for growth in the UK wealth management market, but it will have to deal with the regulatory threat to its core adviser market.
Perpetual sees third-quarter inflow
Perpetual has overcome the departure of its Head of Equities and relatively weak recent performance to post another net inflow of funds.
Amalgamated exceeds expectations
Amalgamated has produced far higher returns than we expected, but should you hold on or is it time to cash in?
Betting on Crown - part 2
Crown plans to invest heavily over the next few years, and valuing the company means estimating the impact it will have on earnings.
GBST downgraded to Hold
Financial software provider GBST has gained 16% since we upgraded it to Buy. We're downgrading to Hold.
Austbrokers under review
The insurance broking industry is rapidly changing. It's time for a closer look.
Betting on Crown - part 1
Concerns over capital expenditure requirements and the impact of a Chinese corruption crackdown have created an opportunity in this casino icon.
GBST downgraded to Hold
Financial software provider GBST has gained 10% since we upgraded it to Buy. We're downgrading to Hold.
Call 1300 880 160
Start a chat
Schedule a call
